COVID-19 hastalarında ACE gen polimorfizminin belirlenmesi

The causal factor behind the respiratory illness COVID-19 is the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This virus poses one of the most formidable challenges to human health in recent centuries, given its high morbidity and mortality rates. In March 2020, the international proclamation by the World Health Organization designated the worldwide dissemination of COVID-19 as a pandemic. The SARS-CoV-2 virus demonstrates an increased proclivity for binding to the angiotensin-converting enzyme-2 (ACE2) receptor. ACE2 and angiotensin-converting enzyme-1 (ACE1) are integral components of the renin-angiotensin-aldosterone system (RAAS) and play a pivotal role in preserving local tissue homeostasis. In the current research, we investigated the ACE I/D (Insertion/Deletion) polymorphism in a total of 141 participants, the sample set of 100 COVID-19 patients and 41 healthy controls employing the polymerase chain reaction technique. The research examines the potential link between ACE genetic variations and the intensity of symptoms caused by SARS-CoV-2. This study aimed to evaluate the association of angiotensin-converting enzyme (ACE1) gene Insertion/Deletion (I/D) polymorphism (rs1799752) with the COVID-19 severity. The mean age of the participants was 49.5 years (ranging from 17 to 94). The data analysis revealed that the p-value to be 0.989 when comparing ACE gene polymorphism in the patient cohort to the control group, hence statistically non-significant. A potential limitation of this study was the relatively small sample size. In summary, no discernable correlation was detected between the I and D allele polymorphism in ACE gene and the severity of symptoms in SARS-CoV-2 patients within the population studied. Keywords: ACE gene, gene polymorphism, Covid-19, angiotensin converting enzyme